{"doc_id": "32409561", "type of study": "Therapy", "title": "", "abstract": "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.\nTo assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).\nMulticentre, open label, randomised controlled trial.\n16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.\n150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).\nHydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).\nMAIN OUTCOME MEASURE : Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle.\nAdverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.\nOf 150 patients, 148 had mild to moderate disease and two had severe disease.\nThe mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days.\nA total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus.\nThe probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%).\nThe difference between groups was 4.1% (95% confidence interval -10.3% to 18.5%).\nIn the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients.\nThe most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients.\nTwo hydroxychloroquine recipients reported serious adverse events.\nAdministration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19.\nAdverse events were higher in hydroxychloroquine recipients than in non-recipients.\nTRIAL REGISTRATION : ChiCTR2000029868.\n\u00a9 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY.\nNo commercial re-use. See rights and permissions.\nPublished by BMJ.\n", "Evidence Map": {"Enrollment": [{"term": "mainly mild to moderate coronavirus disease", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 79}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 124}, {"term": "coronavirus disease 2019 (", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 156}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 33}, {"term": "laboratory confirmed covid-19", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 68}, {"term": "mild to moderate or severe", "negation": "affirmed", "UMLS": {}, "start": 196, "end": 222}, {"term": "hydroxychloroquine recipients", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 92}, {"term": "hydroxychloroquine non-recipients", "negation": "affirmed", "UMLS": {}, "start": 168, "end": 201}, {"term": "mild to moderate disease", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 50}, {"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 69}, {"term": "admitted to hospital", "negation": "negated", "UMLS": {}, "start": 153, "end": 173}, {"term": "persistent mild to moderate covid-19", "negation": "negated", "UMLS": {}, "start": 186, "end": 222}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019 : open label , randomised controlled trial .", "Evidence Elements": {"Participant": [{"term": "mainly mild to moderate coronavirus disease", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 79}], "Intervention": [{"term": "Hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 ( covid-19 ) .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 124}, {"term": "coronavirus disease 2019 (", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 156}], "Intervention": [{"term": "hydroxychloroquine plus standard of care", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 77}, {"term": "standard of care alone", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 114}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 22}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 33}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "Multicentre , open label , randomised controlled trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "SETTING", "Text": "16 government designated covid-19 treatment centres in China , 11 to 29 February 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis ( 75 patients assigned to hydroxychloroquine plus standard of care , 75 to standard of care alone ) .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 33}, {"term": "laboratory confirmed covid-19", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 68}], "Intervention": [{"term": "hydroxychloroquine plus standard of care", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 184}, {"term": "standard of", "negation": "affirmed", "UMLS": {}, "start": 168, "end": 179}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERVENTIONS", "Text": "Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily ( total treatment duration : two or three weeks for patients with mild to moderate or severe disease , respectively ) .", "Evidence Elements": {"Participant": [{"term": "mild to moderate or severe", "negation": "affirmed", "UMLS": {}, "start": 196, "end": 222}], "Intervention": [{"term": "Hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "MAIN OUTCOME MEASURE : Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days , analysed according to the intention to treat principle .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Negative conversion of severe acute respiratory syndrome coronavirus 2", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 93}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone .", "Evidence Elements": {"Participant": [{"term": "hydroxychloroquine recipients", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 92}, {"term": "hydroxychloroquine non-recipients", "negation": "affirmed", "UMLS": {}, "start": 168, "end": 201}], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 81}, {"term": "standard of care alone", "negation": "affirmed", "UMLS": {}, "start": 226, "end": 248}], "Outcome": [{"term": "Adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Of 150 patients , 148 had mild to moderate disease and two had severe disease .", "Evidence Elements": {"Participant": [{"term": "mild to moderate disease", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 50}, {"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 69}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The mean duration from symptom onset to randomisation was 16.6 ( SD 10.5 ; range 3-41 ) days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "mean duration from symptom onset to randomisation", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 53}], "Observation": [{"term": "16.6 ( SD 10.5", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 72}, {"term": "range", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 80}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "A total of 109 ( 73 % ) patients ( 56 standard of care ; 53 standard of care plus hydroxychloroquine ) had negative conversion well before 28 days , and the remaining 41 ( 27 % ) patients ( 19 standard of care ; 22 standard of care plus hydroxychloroquine ) were censored as they did not reach negative conversion of virus .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "standard of care", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 54}, {"term": "standard of care plus hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 100}, {"term": "standard of care", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 54}, {"term": "standard of care plus", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 81}], "Outcome": [{"term": "conversion", "negation": "negated", "UMLS": {}, "start": 116, "end": 126}], "Observation": [{"term": "negative", "negation": "negated", "UMLS": {}, "start": 107, "end": 115}], "Count": [{"term": "73 % )", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 23}, {"term": "27 % )", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 178}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4 % ( 95 % confidence interval 73.8 % to 93.8 % ) , similar to that in the standard of care group ( 81.3 % , 71.2 % to 89.6 % ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "standard of care plus hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 97}, {"term": "standard", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 65}], "Outcome": [{"term": "probability of negative conversion by 28 days", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 49}], "Observation": [{"term": "85.4 %", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 114}, {"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 170}], "Count": []}, "Evidence Propositions": [{"Intervention": "standard of care plus hydroxychloroquine", "Observation": "85.4 %", "Outcome": "probability of negative conversion by 28 days", "Count": ""}, {"Intervention": ["standard"], "Observation": "similar", "Outcome": "probability of negative conversion by 28 days", "Count": ""}]}, {"Section": "RESULTS", "Text": "The difference between groups was 4.1 % ( 95 % confidence interval -10.3 % to 18.5 % ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "difference between groups", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 29}], "Observation": [{"term": "4.1 %", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 39}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "In the safety population , adverse events were recorded in 7 / 80 ( 9 % ) hydroxychloroquine non-recipients and in 21 / 70 ( 30 % ) hydroxychloroquine recipients .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine non-recipients", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 107}], "Outcome": [{"term": "adverse events", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 41}], "Observation": [], "Count": [{"term": "80 ( 9 % )", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 73}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The most common adverse event in the hydroxychloroquine recipients was diarrhoea , reported in 7 / 70 ( 10 % ) patients .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 55}], "Outcome": [{"term": "diarrhoea", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 80}], "Observation": [{"term": "most common", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}], "Count": [{"term": "70 (", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 103}]}, "Evidence Propositions": [{"Intervention": ["hydroxychloroquine"], "Observation": "most common", "Outcome": "diarrhoea", "Count": ""}, {"Intervention": "hydroxychloroquine", "Observation": "", "Count": "70 (", "Outcome": "diarrhoea"}]}, {"Section": "RESULTS", "Text": "Two hydroxychloroquine recipients reported serious adverse events .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 22}], "Outcome": [{"term": "serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 65}], "Observation": [], "Count": [{"term": "Two", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 3}]}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19 .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "negated", "UMLS": {}, "start": 153, "end": 173}, {"term": "persistent mild to moderate covid-19", "negation": "negated", "UMLS": {}, "start": 186, "end": 222}], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 36}, {"term": "standard of care alone", "negation": "negated", "UMLS": {}, "start": 118, "end": 140}], "Outcome": [{"term": "probability of negative conversion", "negation": "negated", "UMLS": {}, "start": 78, "end": 112}], "Observation": [{"term": "significantly higher", "negation": "negated", "UMLS": {}, "start": 57, "end": 77}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Adverse events were higher in hydroxychloroquine recipients than in non-recipients .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine recipients", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 59}, {"term": "non-recipients", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 82}], "Outcome": [{"term": "Adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}], "Observation": [{"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 26}], "Count": []}, "Evidence Propositions": [{"Intervention": ["hydroxychloroquine recipients", "non-recipients"], "Observation": "higher", "Outcome": "Adverse events", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : ChiCTR2000029868 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 Author (s ) ( or their employer (s ) ) 2019 . Re-use permitted under CC BY .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "No commercial re-use . See rights and permissions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by BMJ .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}